News

Under the terms of this agreement, RXi has the option, at its sole discretion, to sell to YA Global Investments newly issued common shares, subject to certain conditions,

The study is a randomized, double-blind, placebo-controlled, dose-ranging study to evaluate the safety, tolerability and efficacy of daily TT-223 treatments for 12 weeks with a six-month follow-up. Approximately

Approximately 48 healthy volunteers participated in the study, with 16 recruited for each of three dose groups. In each dose group, 12 volunteers received a single dose of

The primary objectives of this safety and tolerability study have been achieved. These were to determine the maximum tolerated dose and the dose-limiting toxicities for the agent when

Dyax has utilized phage display to generate on behalf of Biogen Idec high affinity, fully human antibody product candidates, including BIIB-022, currently in Phase I clinical trials for

The awarding of the patent thus allows to analyze by high-throughput processes to which extent such drug candidates block the export of viral messenger RNA from the cell

Each of the 39 separate Blue Cross and Blue Shield companies, acting independently, now has the opportunity to enter into an ancillary contract to access FAMILION LQTS tests

Cope also served for a number of years as the Ernest W. Volwiler Fellow and head, cancer and AIDS research effort for Abbot Laboratories-Ross Division. Cope is active

The data show that treatment with cyclopamine, the natural product foundation of IPI-926, in animals bearing grafts of primary ovarian cancer resulted in significant tumor growth inhibition compared